Publications
|
Astara K, Pournara C, de Natale E.R, Wilson H, Vavougios G, Lappas A, Politis M, Christodoulou N. Premises and Perspectives for the Functionality of the Glymphatic System. Journal of Neurophysiology. 2023 May 1;129(5):1228-1236. |
|
De Natale E.R, Wilson H, Udeh-Momoh C, Ford J.K, Politis M, Middleton L.T. How molecular imaging studies can disentangle in vivo disease mechanisms in age-related neurodegenerative disorders. Aging. 2023; 455-492. https://www.sciencedirect.com/science/article/abs/pii/B9780128237618000227?via%3Dihub |
|
Verghese J.P, Terry A, de Natale E.R, Politis M. Research evidence of pharmacological modulation of the glymphatic system in neurodegenerative diseases. Journal of Clinical Medicine. 2022 Nov 25;11(23):6964. |
|
de Natale E.R, Wilson H, and Politis M. Parkinson’s disease and related disorders: The pursuit for reliable readouts and the role of neuroimaging. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 3-20 ISBN: 978-0-12-821651-4. 2022 |
|
Wilson H, de Natale E.R, Politis M. Advances in Magnetic Resonance Imaging. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 21-52 ISBN: 978-0-12-821651-4. 2022 |
|
Wilson H, Politis M. Advances in Molecular Neuroimaging Methodology. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 53-68 ISBN: 978-0-12-821651-4. 2022 |
|
de Natale E.R, Wilson H, Politis M. Dopaminergic molecular imaging in familial and idiopathic Parkinson’s disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 69-104 ISBN: 978-0-12-821651-4. 2022 |
|
Wilson H, Terry A, Politis M. Molecular imaging beyond dopamine and serotonin in familial and idiopathic Parkinson’s disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 121-150 ISBN: 978-0-12-821651-4. 2022 |
|
Verghese J.P, de Natale E.R, Politis M. Structural MRI in familial and idiopathic Parkinson’s disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 151-200 ISBN: 978-0-12-821651-4. 2022 |
|
de Natale E.R, Wilson H, Politis M. Dopaminergic molecular imaging in familial and idiopathic Parkinson’s disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 69-104 ISBN: 978-0-12-821651-4. 2022 |
|
Wilson H, Terry A, Politis M. Molecular imaging beyond dopamine and serotonin in familial and idiopathic Parkinson’s disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 121-150 ISBN: 978-0-12-821651-4. 2022 |
|
Verghese J.P, de Natale E.R, Politis M. Structural MRI in familial and idiopathic Parkinson’s disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 151-200 ISBN: 978-0-12-821651-4. 2022 |
|
de Natale E.R, Verghese J.P., Wilson H, Politis M. Molecular imaging in prodromal Parkinson's disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 251-274 ISBN: 978-0-12-821651-4. 2022 |
|
de Natale E.R, Wilson H, Politis M, Niccolini F. Neuroimaging in Progressive Supranuclear Palsy. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 355-398 ISBN: 978-0-12-821651-4. 2022 |
|
Wilson H, de Natale E.R, Politis M, Niccolini F. Neuroimaging in Corticobasal Syndrome. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 399-420 ISBN: 978-0-12-821651-4. 2022 |
|
de Natale E.R, Wilson H, Niccolini F, Politis M. Molecular imaging in Huntington's Disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 421-448 ISBN: 978-0-12-821651-4. 2022 |
|
Belogianni C, Wilson H, de Natale E.R, Politis M. Magnetic Resonance Imaging in Huntington’s disease. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 449-490 ISBN: 978-0-12-821651-4. 2022 |
|
Terry A, de Natale E.R, Politis M. Neuroimaging in Essential Tremor. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 491-518. ISBN: 978-0-12-821651-4. 2022 |
|
de Natale E.R, Wilson H, Politis M. Neuroimaging of Restless legs syndrome. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 519-540 ISBN: 978-0-12-821651-4. 2022 |
|
Terry A, de Natale E.R, Politis M. Neuroimaging in Dystonia. Neuroimaging in Parkinson's Disease and Related Disorders. Page 541-566 ISBN: 978-0-12-821651-4. 2022 |
|
Tondo G, Comi C, Naldi A, de Natale E.R, Politis M. Neuroimaging in Multiple System Atrophy. Neuroimaging in Parkinson's Disease and Related Disorders. Pages 311-354. ISBN: 978-0-12-821651-4. 2022 |
|
Wilson, H., de Natale, E.R., Politis, M. Concise Review: Recent advances in neuroimaging techniques to assist clinical trials on cell-based therapies in neurodegenerative diseases. Stem Cells. 2022 Aug 25;40(8):724-735. |
|
Ford, J., Kafetsouli, D., Wilson, H., Udeh-Momoh, C., Politis, M., AhmadiAbhri, S., Rabiner, I., Middleton, L.T. At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer’s Disease and Related Research. Journal of Prevention of Alzheimer's Disease. 2022;9(1):67-76. |
|
de Natale, E.R., Wilson, H., Politis, M. Predictors of RBD progression and conversion to synucleinopathies. Current Neurology and Neuroscience Reports. 2022 Feb;22(2):93-104 |
|
De Natale E.R., Wilson H., Politis M. Imaging Biomarkers in Huntington’s Disease. In: Peplow P.V., Martinez B., Gennarelli T.A. (eds) Neurodegenerative Diseases Biomarkers. Neuromethods. 2022; vol 173. Humana, New York, NY. https://experiments.springernature.com/articles/10.1007/978-1-0716-1712-0_19 |
|
Wilson, H., De Natale, E.R., Politis, M. Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson’s disease. Handbook of Clinical Neurology. 2021;179:189-205. |
|
De Natale E.R, Wilson H, Politis M. Serotonergic imaging in Parkinson’s disease. Progress in Brain Research. 2021; 261:303-338. |
|
Chandra A, Farrell C, Wilson H, Dervenoulas G, de Natale E.R, Politis M. Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer’s disease spectrum. Neurobiology of Aging. 2021 Jan;97:1-9. |
|
King-Robson J, Wilson H, Politis M; Alzheimer’s Disease Neuroimaging Initiative. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimers Disease. 2021;82(2):541-560. |
|
Wilson, H., Politis, M., Rabiner, E.A., Middleton, L. Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. Cells. 2020 Dec 2;9(12):2581. |
|
Wilson, H., Pagano, G., de Natale, E.R, Mansure, A., Caminiti, S.P., Polychronis, S., Middleton, L.T., Price, G., Schmidt, K.F., Gunn, R.G., Rabiner, E.A., Politis, M. Mitochondrial complex 1, sigma 1 and synaptic vesicle 2A in early drug-naïve Parkinson’s disease. Move Disorder, 2020 Aug;35(8):1416-1427. |
|
Carotenuto, A., Wilson, H., Giordano, B., Caminiti, S.P., Chappell, Z., Williams, S.C.R., Hammers, A., Silber, E., Brex, P., Politis, M. Impaired connectivitiy within neuromodulatory networks in multiple sclerosis and clinical implications. J Neurol. 26 March 2020. doi: 10.1007/s00415-020-09806-3. |
|
Wilson, H., Pagano, G., Yousaf, T., Polychronis, S., De Micco., Giordano, B., Niccolini, F., Politis, M. Predictive cognitive decline with linical markers in Parkinson’s disease (PRECODE-1). J Neural Transm. Jan 2020. 127(1), 51-59. DOI: 10.1007/s00702-019-02125-6 https://link.springer.com/article/10.1007/s00702-019-02125-6 |
|
Niccolini, F., Wilson, H., Giordano, B., Diamantopoulos, K., Pagano, G., Chaudhuri, K. R., Politis, M. Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. BMC neuroscience. 22 Oct 2019. doi: 10.1186/s12868-019-0537-1 https://bmcneurosci.biomedcentral.com/articles/10.1186/s12868-019-0537-1 |
|
Carotenuto A, Giordano B, Dervenoulas G, Wilson H, Veronese M, Chappell Z, Polychronis S, Pagano G, Mackewn J, Turkheimer FE, Williams SCR, Hammers A, Silber E, Brex P, Politis M. [18F]florbetapir-PET/MR imaging to assess demyelination in multiple sclerosis. Eur J Nucl Med Mol Imaging. 2019 Oct 21. doi: 10.1007/s00259-019-04533-y. https://link.springer.com/article/10.1007/s00259-019-04533-y |
|
Wilson H, Dervenoulas G, Pagano G, Tyacke RJ, Polychronis S, Myers J, Gunn RN, Rabiner EA, Nutt D, Politis M. Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: an in vivo11C-BU99008 PET study, Brain, Volume 142, Issue 10, October 2019, Pages 3116-3128, https://doi.org/10.1093/brain/awz260 https://academic.oup.com/brain/article-abstract/142/10/3116/5554562?redirectedFrom=fulltext |
|
Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M. Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019 Aug;18(8):748-759. doi: 10.1016/S1474-4422(19)30140-1. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30140-1/fulltext |
|
Pagano G, Niccolini F, Wilson H, Yousaf T, Khan NL, Martino D, Plisson C, Gunn RN, Rabiner EA, Piccini P, Foltynie T, Politis M.Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. Mov Disord. 2019 Jun 3. doi: 10.1002/mds.27733. |
|
Wilson H, Pagano G, Niccolini F, Muhlert N, Mehta MA, Searle G, Gunn RN, Rabiner EA, Foltynie T, Politis M. The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. Parkinsonism Relat Disord. 2019 Feb 22. pii: S1353-8020(19)30073-2. doi: 10.1016/j.parkreldis.2019.02.027. https://www.prd-journal.com/article/S1353-8020(19)30073-2/fulltext |
|
Wilson H, Niccolini F, Pellicano C, Politis M. Cortical thinning across Parkinson's disease stages and clinical correlates. J Neurol Sci. 2019 Mar 15; 398:31-38. doi: 10.1016/j.jns.2019.01.020. https://www.jns-journal.com/article/S0022-510X(19)30020-6/fulltext |
|
Wilson H, Pagano G, Politis M. Dementia spectrum disorders: lessons learnt from decades with PET research. J Neural Transmission. 2019 Mar; 126(3):233-251. doi: 10.1007/s00702-019-01975-4. https://link.springer.com/article/10.1007%2Fs00702-019-01975-4 |
|
Wilson H, Politis M. Structural Magnetic Resonance Imaging in Huntington’s Disease. International Review of Neurobiology. 2018; Volume 142, pages 335-380.doi: 10.1016/bs.irn.2018.09.006. https://www.sciencedirect.com/science/article/pii/S0074774218301065?via%3Dihub |
|
Wilson H, Politis M. Molecular Imaging in Huntington’s Disease. International Review of Neurobiology. 2018; Volume 142, pages 289-333. doi: 10.1016/bs.irn.2018.08.007. https://www.sciencedirect.com/science/article/pii/S0074774218300746?via%3Dihub |
|
De Natale E, Niccolini F, Wilson H, Politis M. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson’s Disease. International Review of Neurobiology. 2018; Volume 141, page 131-172. doi: 10.1016/bs.irn.2018.08.003. https://www.sciencedirect.com/science/article/pii/S0074774218300680?via%3Dihub |
|
De Natale E, Wilson H, Pagano G, Politis M. Imaging Transplantation in Movement Disorders. Int Rev Neurobiol. 2018;143:213-263. doi: 10.1016/bs.irn.2018.10.002. https://www.sciencedirect.com/science/article/pii/S0074774218301314?via%3Dihub |
|
Cousins O, Yousaf T, Wilson H, Pagano G, Politis M. Molecular Imaging of Dementia with Lewy Bodies. International Review of Neurobiology. 2018; Volume 144; pages 59-93. doi: 10.1016/bs.irn.2018.10.007. https://www.sciencedirect.com/science/article/pii/S0074774218301363?via%3Dihub |
|
Tondo G, Esposito M, Dervenoulas G, Wilson H, Politis M. Hybrid PET-MRI application in Movement Disorders. International Review of Neurobiology. 2018; Volume 144; pages 211-257. doi: 10.1016/bs.irn.2018.10.003. https://www.sciencedirect.com/science/article/pii/S0074774218301326?via%3Dihub |
|
Yousaf T, Pagano G, Wilson H, Politis M. Neuroimaging of Sleep Disturbances in Movement Disorders. Frontiers in Neurology. 2018; https://doi.org/10.3389/fneur.2018.00767 https://www.frontiersin.org/articles/10.3389/fneur.2018.00767/full |
|
Wilson H, Niccolini F, Hirschbichler S, Yousaf T, Pagano G, Whittington A, Caminiti SP, Erro R, Holton JL, Jaunmuktane Z, Esposito M, Martino D, Abdul A, Passchier J, Rabiner EA, Gunn RN, Bhatia KP, Politis M; Alzheimer’s Disease Neuroimaging Initiative. Disease-related patterns of in vivo pathology in Corticobasal syndrome. Eur J Nucl Med Mol Imaging. 2018; doi: 10.1007/s00259-018-4104-2. |
|
Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018 Sep 4;91(10):e894-e905. doi: 10.1212/WNL.0000000000006134. |
|
Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, Politis M. Diabetes Mellitus and Parkinson’s disease. Neurology. 2018; 8;90(19):e1654-e1662. doi: 10.1212/WNL.0000000000005475 |
|
Schulz J, Pagano G, Bonfante J, Wilson H, Politis M. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease. Brain 2018; 141(5):1501-1516; https://doi.org/10.1093/brain/awy072 |
|
Wilson, H., Giordano, B., Federico, T., Ray Chaudhuri, K., and Politis, M. Serotonergic dysregulation is linked to sleep problems in Parkinson’s disease. Neuroimage Clinical 2018; doi:10.1016/j.nicl.2018.03.001. https://www.sciencedirect.com/science/article/pii/S2213158218300718 |
|
Niccolini F, Mencacci NE, Yousaf T, Rabiner EA, Salpietro V, Pagano G, Balint B, Efthymiou S, Houlden H, Gunn RN, Wood N, Bhatia KP, Politis M. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27523. |
|
Yousaf T, Dervenoulas G, Politis M. Advances in MRI Methodology. Int Rev Neurobiol. 2018;141:31-76. doi: 10.1016/bs.irn.2018.08.008. https://www.sciencedirect.com/science/article/pii/S0074774218300758?via%3Dihub |
|
Pagano G, Politis M. Molecular Imaging of the Serotonergic System in Parkinson's Disease. Int Rev Neurobiol. 2018;141:173-210. oi: 10.1016/bs.irn.2018.08.002. https://www.sciencedirect.com/science/article/pii/S0074774218300679?via%3Dihub |
|
Chandra A, Dervenoulas G, Politis M; Alzheimer’s Disease Neuroimaging Initiative. Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. J Neurol. 2018 Aug 17. doi: 10.1007/s00415-018-9016-3. https://link.springer.com/article/10.1007%2Fs00415-018-9016-3 |
|
Yousaf T, Dervenoulas G, Valkimadi PE, Politis M. Neuroimaging in Lewy body dementia. J Neurol. 2018 May 14. doi: 10.1007/s00415-018-8892-x. https://link.springer.com/article/10.1007%2Fs00415-018-8892-x |
|
Nørgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, Lubberink M, Parsey RV, Politis M, Rabiner EA, Slifstein M, Sossi V, Suhara T, Talbot PS, Turkheimer F, Strother SC, Knudsen GM. Cerebral serotonin transporter measurements with [11C]DASB: A review on acquisition and preprocessing across 21 PET centres. J Cereb Blood Flow Metab. 2018 Jan 1:271678X18770107. doi: 10.1177/0271678X18770107. |
|
Yousaf, T., Wilson, H., and Politis M. Imaging the Nonmotor Symptoms in Parkinson’s Disease. International Review of Neurobiology 2017; 133:179-257. doi: 10.1016/bs.irn.2017.05.001. https://www.sciencedirect.com/science/article/pii/S0074774217300454?via%3Dihub |
|
Pagano G, Yousaf T, Wilson H, Niccolini F, Polychronis S, Chaudhuri KR, Politis M. Constipation is not associated with DAT dopaminergic pathology in early de novo patients with Parkinson’s disease. Eur J Neurol. 2017 Oct 27. doi: 10.1111/ene.13503. |
|
Niccolini, F., Wilson, H., Pagano, G., Coello, C., Searle, G., Roger, G., Rabiner, E., Foltynie, T., and Politis, M. Loss of phosphodiesterase 4 in Parkinson’s disease: Relevance to cognitive deficits. Neurology 2017; 89:586-593. DOI: https://doi.org/10.1212/WNL.0000000000004201 |
|
Moonga, I., Niccolini, F., Wilson, H., Pagano, G., and Politis, M. Hypertension and Alzheimer’s disease. European Journal of Neurology 2017; 24:1173-1182. https://doi.org/10.1111/ene.13374 |
|
Pagano, G., Tayyabah, Y., Wilson, H., Niccolini, F., Polychronis, S., Ray Chaudhuri, K., and Politis, M. Urinary dysfunction as marker of a worse phenotype of Parkinson’s disease. Movement Disorders 2017; 32:939-940. https://doi.org/10.1002/mds.26967 |
|
Politis, M., Wilson, H., Wu, K., Brooks, D., and Piccini, P. Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in PD. Neuroimage Clinical 2017; 16:455-460. doi: 10.1016/j.nicl.2017.08.013. https://www.sciencedirect.com/science/article/pii/S2213158217302012?via%3Dihub |
|
Wilson, H., De Micco, R., Niccolini, F., and Politis, M. Molecular imaging markers to track Huntington’s disease pathology. Frontiers in Neurology 2017; 8:11. doi: 10.3389/fneur.2017.00011. https://www.frontiersin.org/articles/10.3389/fneur.2017.00011/full |
|
Yousaf T, Pagano G, Niccolini F, Politis M. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. J Neurol Sci. 2018 Apr 15;387:220-227. doi: 10.1016/j.jns.2018.02.032. https://www.jns-journal.com/article/S0022-510X(18)30090-X/fulltext |
|
Yousaf T, Pagano G, Niccolini F, Politis M. Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. Sleep Med. 2018 Mar;43:25-30. doi: 10.1016/j.sleep.2017.11.1137. https://www.sciencedirect.com/science/article/abs/pii/S1389945717315824?via%3Dihub |
|
Noyce AJ, Dickson J, Rees RN, Bestwick JP, Isaias IU, Politis M, Giovannoni G, Warner TT, Lees AJ, Schrag A. Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27282. |
|
Pagano G, Niccolini F, Politis M. The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. J Neural Transm (Vienna). 2017 Dec 20. doi: 10.1007/s00702-017-1823-7. |
|
Niccolini F, Diamantopoulos K, Kiosses S, Politis M. Be vigilant for dementia in Parkinson’s disease. Practitioner. 2017 May;261(1804):11-5. |
|
Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P. 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.Mov Disord. 2018 Jan;33(1):117-127. doi: 10.1002/mds.27183. |
|
Pagano G, Yousaf T, Politis M. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease. Curr Neurol Neurosci Rep. 2017 Oct 3;17(11):90. doi: 10.1007/s11910-017-0794-2. https://link.springer.com/article/10.1007%2Fs11910-017-0794-2 |
|
Niccolini F, Pagano G, Fusar-Poli P, Wood A, Mrzljak L, Sampaio C, Politis M. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):185-196. doi: 10.1136/jnnp-2017-316633. |
|
Qamar MA, Sauerbier A, Politis M, Carr H, Loehrer P, Chaudhuri KR. Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis? NPJ Parkinsons Dis. 2017 Jan 25;3:5. doi: 10.1038/s41531-016-0006-9. |
|
Mehranian A, Belzunce M, Niccolini F, Politis M, Prieto C, Turkheimer F, Hammers A, Reader A. PET image reconstruction using multi-parametric anato-functional priors. Phys Med Biol. 2017 Jun 1. doi: 10.1088/1361-6560/aa7670. doi: 10.1088/1361-6560/aa7670. |
|
Politis M, Pagano G, Niccolini F. Imaging in Parkinson's Disease. Int Rev Neurobiol. 2017;132:233-274. doi: 10.1016/bs.irn.2017.02.015. |
|
Politis M. Disease progression in LRRK2 parkinsonism. Lancet Neurol. 2017 May;16(5):334-335. doi: 10.1016/S1474-4422(17)30082-0. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30082-0/fulltext |
|
Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Mar 3. doi: 10.1038/nrneurol.2017.27. |
|
Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, Piccini P, Politis M, Thobois S, Ceravolo R, Higuchi M, Kaasinen V, Masellis M, Peralta MC, Obeso I, Pineda-Pardo JÁ, Cilia R, Ballanger B, Niethammer M, Stoessl JA; IPMDS-Neuroimaging Study Group. Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 2017 Feb;32(2):181-192. doi: 10.1002/mds.26907. |
|
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81-95. oi: 10.1038/nrneurol.2016.200. |
|
Politis M. A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016): Reply to Jean-Claude Baron Letter to Editor. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):548-550. doi: 10.1007/s00259-016-3597-9. https://link.springer.com/article/10.1007%2Fs00259-016-3597-9 |
|
Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE, Tabrizi SJ, Piccini P. Corrigendum to "Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers" [Neurobiol. Dis. 83 (2015) 115-121]. Neurobiol Dis. 2017 Feb; 98:162. doi: 10.1016/j.nbd.2016.12.003. https://www.sciencedirect.com/science/article/pii/S0969996116302844?via%3Dihub |
|
Pagano G, Niccolini F, Fusar-Poli P, Politis M. Serotonin transporter in Parkinson's disease: A meta-analysis of PET studies. Ann Neurol. 2017 Feb;81(2):171-180. doi: 10.1002/ana.24859. |
|
Martin-Bastida A, Lao-Kaim NP, Loane C, Politis M, Roussakis AA, Valle-Guzman N, Kefalopoulou Z, Paul-Visse G, Widner H, Xing Y, Schwarz ST, Auer DP, Foltynie T, Barker RA, Piccini P. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. Eur J Neurol. 2017 Feb;24(2):357-365. doi: 10.1111/ene.13208. |
|
Wilson, H., Niccolini, N., Haider, S., Reis Marques, T., Pagano, P., Coello, C., Natesan, S., Kapur, S., Rabiner, E.A., Gunn, R.N., Tabrizi, S.J., and Politis, M. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington’s disease gene carriers. Journal of Neurological Sciences 2016; 368:243-248. 10.1016/j.jns.2016.07.033. https://www.jns-journal.com/article/S0022-510X(16)30445-2/fulltext |
|
Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B, Brooks DJ, Chaudhuri KR, Piccini P. Sustained Striatal Dopamine Levels Following Intestinal Levodopa infusions in Parkinson’s disease patients. Mov Disord. 2016; doi: 10.1002/mds.26848. |
|
Schrag A, Politis M. Serotonergic loss underlying apathy in Parkinson's disease. Brain. 2016;139(Pt 9):2338-9. doi: 10.1093/brain/aww190. |
|
Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med (Lond). 2016; 16(4):371-5. doi: 10.7861/clinmedicine.16-4-371. |
|
Niccolini F, Politis M. A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. Eur J Nucl Med Mol Imaging. 2016 Jul 28. DOI 10.1007/s00259-016-3464-8 https://link.springer.com/article/10.1007%2Fs00259-016-3464-8 |
|
Asharaghi MR, Pagano G, Polychronis S, Niccolini F, Politis M. Parkinson’s Disease, Diabetes and Cognitive Impairment. Recent Pat Endocr Metab Immune Drug Discov. 2016 Jun 30. DOI: 10.2174/1872214810999160628105549 |
|
Loane C, Politis M, Kefalopoulou Z, Valle-Guzman N, Paul G, Widner H, Foltynie T, Barker RA, Piccini P. Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Mov Disord. 2016;31(7):1020-6. doi: 10.1002/mds.26606. |
|
Diggle CP, Sukoff Rizzo SJ, Popiolek M, Hinttala R, Schülke JP, Kurian MA, Carr IM, Markham AF, Bonthron DT, Watson C, Sharif SM, Reinhart V, James LC, Vanase-Frawley MA, Charych E, Allen M, Harms J, Schmidt CJ, Ng J, Pysden K, Strick C, Vieira P, Mankinen K, Kokkonen H, Kallioinen M, Sormunen R, Rinne JO, Johansson J, Alakurtti K, Huilaja L, Hurskainen T, Tasanen K, Anttila E, Marques TR, Howes O, Politis M, Fahiminiya S, Nguyen KQ, Majewski J, Uusimaa J, Sheridan E, Brandon NJ. Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. Am J Hum Genet. 2016 Apr 7;98(4):735-43. doi: 10.1016/j.ajhg.2016.03.015. |
|
Roy R, Niccolini F, Pagano G, Politis M. Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging. 2016 Mar 16. doi: 10.1007/s00259-016-3349-x. https://link.springer.com/article/10.1007%2Fs00259-016-3349-x |
|
Roussakis AA, Politis M, Towey D, Piccini P. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias. Neurology. 2016 Mar 22;86(12):1152-8. doi: 10.1212/WNL.0000000000002494. |
|
Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington's disease. Eur J Nucl Med Mol Imaging. 2016 Feb 22. doi: 10.1007/s00259-016-3324-6. https://link.springer.com/article/10.1007%2Fs00259-016-3324-6 |
|
Marques TR, Natesan S, Niccolini F, Politis M, Gunn RN, Searle GE, Howes O, Rabiner EA, Kapur S. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [11C]IMA107. Am J Psychiatry. 2016 Feb 19. doi: 10.1176/appi.ajp.2015.15040518. |
|
Loane C, Wu K, O'Sullivan SS, Lawrence AD, Woodhead Z, Lees AJ, Piccini P, Politis M. Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism Relat Disord. 2015 Nov;21(11):1336-41. doi: 10.1016/j.parkreldis.2015.09.042. https://www.prd-journal.com/article/S1353-8020(15)00433-2/fulltext |
|
Pellicano C, Niccolini F, Wu K, O'Sullivan SS, Lawrence AD, Lees AJ, Piccini P, Politis M. Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. J Neurol. 2015 Dec;262(12):2653-61. doi: 10.1007/s00415-015-7892-3. https://link.springer.com/article/10.1007%2Fs00415-015-7892-3 |
|
Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE, Tabrizi SJ, Piccini P. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiol Dis. 2015 Nov;83:115-21. doi: 10.1016/j.nbd.2015.08.011. https://www.sciencedirect.com/science/article/abs/pii/S0969996115300322?via%3Dihub |
|
Niccolini F, Foltynie T, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN, Piccini P, Politis M. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Brain. 2015 Oct;138(Pt 10):3003-15. doi: 10.1093/brain/awv219. |
|
Niccolini F, Haider S, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Piccini P, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain. 2015 Oct;138(Pt 10):3016-29. doi: 10.1093/brain/awv214. |
|
Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Bose S, Lees AJ, Piccini P. Single versus multiple impulse control disorders in Parkinson's disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. J Neurol. 2015; 262(6):1504-14. doi: 10.1007/s00415-015-7722-7. https://link.springer.com/article/10.1007%2Fs00415-015-7722-7 |
|
Politis M, Niccolini F. Serotonin in Parkinson's disease. Behav Brain Res. 2015 Jan 15;277:136-45. doi: 10.1016/j.bbr.2014.07.037. https://www.sciencedirect.com/science/article/pii/S0166432814004860?via%3Dihub |
|
Rocchi L, Niccolini F, Politis M. Recent imaging advances in neurology. J Neurol. 2015; 262(9):2182-9. doi: 10.1007/s00415-015-7711-x. https://link.springer.com/article/10.1007%2Fs00415-015-7711-x |
|
Niccolini F, Rocchi L, Politis M. Molecular imaging of levodopa-induced dyskinesias. Cell Mol Life Sci. 2015 Jun;72(11):2107-17. doi: 10.1007/s00018-015-1854-x. https://link.springer.com/article/10.1007%2Fs00018-015-1854-x |
|
Smith R, Wu K, Hart T, Loane C, Brooks DJ, Björklund A, Odin P, Piccini P, Politis M. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiol Aging. 2015 Apr;36(4):1736-42. doi: 10.1016/j.neurobiolaging.2014.12.037. https://www.sciencedirect.com/science/article/abs/pii/S0197458014008549?via%3Dihub |
|
Giannetti P, Politis M, Su P, Turkheimer FE, Malik O, Keihaninejad S, Wu K, Waldman A, Reynolds R, Nicholas R, Piccini P. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain. 2015 Jan;138(Pt 1):110-9. doi: 10.1093/brain/awu331. |
| 2014 |
|---|
|
Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014 Dec;10(12):708-22. doi: 10.1038/nrneurol.2014.205. |
|
Turkheimer FE, Bodini B, Politis M, Pariante CM, Ciccarelli O, Yeo RA. The X-Linked Hypothesis of Brain Disorders: Can Gender Ratios Tell Us Anything About Cellular Etiology of Neurodegenerative and Psychiatric Diseases? Neuroscientist. 2014 Aug 8. doi: 10.1177/1073858414545999. |
|
Niccolini F, Politis M. Neuroimaging in Huntington's disease. World J Radiol. 2014 Jun 28;6(6):301-12. doi: 10.4329/wjr.v6.i6.301. |
|
Niccolini F, Su P, Politis M. Dopamine receptor mapping with PET imaging in Parkinson's disease. J Neurol. 2014 Mar 15. doi: 10.1007/s00415-014-7302-2. https://link.springer.com/article/10.1007%2Fs00415-014-7302-2 |
|
Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Lees A, Piccini P. Problematic Internet use in Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb 5. doi: 10.1016/j.parkreldis.2014.01.019. https://www.prd-journal.com/article/S1353-8020(14)00035-2/fulltext |
|
Niccolini F, Su P, Politis M. PET in Multiple Sclerosis. Clin Nucl Med. 2014 Feb 20. doi: 10.1097/RLU.0000000000000359. https://journals.lww.com/nuclearmed/Abstract/2015/01000/PET_in_Multiple_Sclerosis.35.aspx |
|
Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest. 2014 Mar 3;124(3):1340-9. doi: 10.1172/JCI71640. |
|
Giannetti P, Politis M, Su P, Turkheimer F, Malik O, Keihaninejad S, Wu K, Reynolds R, Nicholas R, Piccini P. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis. 2014 Feb 6;65C:203-210. doi: 10.1016/j.nbd.2014.01.018. https://www.sciencedirect.com/science/article/abs/pii/S0969996114000321?via%3Dihub |
|
Niccolini F, Loane C, Politis M. Dyskinesias in Parkinson's disease: views from positron emission tomography studies. Eur J Neurol. 2014 Jan 28. doi: 10.1111/ene.12362. |
|
Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, Widner H, Rehncrona S, Brundin P, Björklund A, Lindvall O, Limousin P, Quinn N, Foltynie T. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 2014 Jan;71(1):83-7. doi: 10.1001/jamaneurol.2013.4749. https://jamanetwork.com/journals/jamaneurology/fullarticle/1765680 |
|
2013 |
|
Garvey LJ, Pavese N, Politis M, Ramlackhansingh A, Brooks DJ, Taylor-Robinson SD, Winston A. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART; An 11C-PK11195 PET study. AIDS. 2013 Jul 24. doi: 10.1097/01.aids.0000432467.54003.f7. |
|
Roussakis AA, Piccini P, Politis M. Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. Degenerative Neurological and Neuromuscular Disease. 2013; 3:33-39. doi: 10.2147/DNND.S19807. |
|
Loane C, Pilinis C, Lekkas TD, Politis M. Ambient particulate matter and its potential neurological consequences. Rev Neurosci. 2013;24(3):323-35. doi: 10.1515/revneuro-2013-0001. |
|
Loane C, Wu K, Bain P, Brooks DJ, Piccini P, Politis M. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology. 2013 May 14;80(20):1850-5. doi: 10.1212/WNL.0b013e318292a31d. |
|
Politis M, Loane C, Wu K, O'Sullivan SS, Woodhead Z, Kiferle L, Lawrence AD, Lees AJ, Piccini P. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain. 2013 Feb;136(Pt 2):400-11. doi: 10.1093/brain/aws326. |
|
2012 |
|
Politis M, Piccini P. In vivo imaging of the integration and function of nigral grafts in clinical trials. Prog Brain Res. 2012;200:199-220. doi: 10.1016/B978-0-444-59575-1.00009-0. |
|
Politis M, Loane C. Reduplicative paramnesia: a review. Psychopathology. 2012;45(6):337-43. oi: 10.1159/000337748. |
|
Wu K, O'Keeffe D, Politis M, O'Keeffe GC, Robbins TW, Bose SK, Brooks DJ, Piccini P, Barker RA. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain. 2012 Aug;135(Pt 8):2449-57. doi: 10.1093/brain/aws157. |
|
Garvey LJ, Pavese N, Ramlackhansingh A, Thomson E, Allsop JM, Politis M, Kulasegaram R, Main J, Brooks DJ, Taylor-Robinson SD, Winston A. Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PLoS One. 2012;7(7):e38980. doi: 10.1371/journal.pone.0038980. |
|
Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, Waldman A, Malik O, Matthews PM, Reynolds R, Nicholas R, Piccini P. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology. 2012 Aug 7;79(6):523-30. doi: 10.1212/WNL.0b013e3182635645. |
|
Wu K, Politis M, Piccini P. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad Med J. 2012, 8: 235-246. doi: 10.1136/pgmj.2008.075820. |
|
Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol. 2012;3:96. doi: 10.3389/fphar.2012.00096. |
|
Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012 Jun 21;1461:111-8. doi: 10.1016/j.brainres.2012.04.032. |
|
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Björklund A, Lindvall O, Piccini P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med. 2012 Apr 4;4(128):128ra41. doi: 10.1126/scitranslmed.3003391. |
|
Su P and Politis M. The role of microglia in neurodegenerative disease. In: Microglia: Biology, Functions and Roles in Disease. Editors: Kaur C, Eng-Ang L (eds). Microglia: Biology, functions and roles in disease, New York: Nova publishers, 2012, 93-117. http://www.novapublishers.org/catalog/product_info.php?products_id=41433 |
|
Politis M, Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol. 2012 Sep;259(9):1769-80. https://doi.org/10.1007/s00415-012-6428-3 https://link.springer.com/article/10.1007%2Fs00415-012-6428-3 |
|
Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med. 2012 Jan 4;10:1. doi: 10.1186/1741-7015-10-1. |
|
2011 |
|
Kiferle L, Politis M, Muraro PA, Piccini P. Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur J Neurol. 2011 Feb;18(2):226-31. doi: 10.1111/j.1468-1331.2010.03154.x. |
|
Politis M, Loane C. Serotonergic dysfunction in Parkinson's disease and its relevance to disability. Scientific World Journal. 2011;11:1726-34. doi: 10.1100/2011/172893. |
|
Loane C, Politis M. Positron emission tomography neuroimaging in Parkinson's disease. Am J Transl Res. 2011 Aug 15;3(4):323-41. ISSN:1943-8141/AJTR1105001 |
|
Politis M, Loane C, Wu K, Brooks DJ, Piccini P. Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiol Dis. 2011 Sep;43(3):609-15. doi: 10.1016/j.nbd.2011.05.009. |
|
Su P, Loane C and Politis M. The use of stem cells in the treatment of Parkinson’s disease. Insiences J. 2011, 1(3), 136-156. doi:10.5640/insc.0103136 https://pdfs.semanticscholar.org/47a4/92b0761c5783201bf31155838b1729e83b78.pdf |
|
Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P. Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord. 2011 Sep;26(11):1997-2003. doi: 10.1002/mds.23743. |
|
Politis M. Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC Med. 2011 May 10;9:50. doi: 10.1186/1741-7015-9-50. |
|
O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, Piccini P. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain. 2011 Apr;134(Pt 4):969-78. doi: 10.1093/brain/awr003. |
|
Loane C, Su P and Politis M. Different Dyskinesias in Parkinson’s Disease and Their Relationship to Levodopa. European Neurological Journal. July 2011 3(1): 20-26. |
|
Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp. 2011 Feb;32(2):258-70. doi: 10.1002/hbm.21008. |
|
2010 |
|
Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, Brooks DJ, Piccini P. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis. 2010 Feb;37(2):356-61. doi: 10.1016/j.nbd.2009.10.015. |
|
Politis M and Loane C. Ch 5: Imaging Dyskinesias in Parkinson’s Disease. In Diagnosis and Treatment of Parkinson’s Disease. 69-88. Rana AQ (ed). InTech, 2011 |
|
Politis M. Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? BMC Med. 2010 Dec 2;8:80. doi: 10.1186/1741-7015-8-80. https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-8-80 |
|
Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010 Nov 23;75(21):1920-7. doi: 10.1212/WNL.0b013e3181feb2ab. |
|
Politis M, Piccini P. Brain imaging after neural transplantation. Prog Brain Res. 2010;184:193-203. doi: 10.1016/S0079-6123(10)84010-5. |
|
Politis M, Wu K, Molloy S, G Bain P, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010 Aug 15;25(11):1646-51. doi: 10.1002/mds.23135. |
|
Piccini P and Politis M. Cell-Based Therapies: Imaging Outcomes. Imaging in PD. Eidelberg (ed). Oxford University Press, 2010, 173-180. |
|
Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010 Oct;40(1):216-21. doi: 10.1016/j.nbd.2010.05.028. |
|
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med. 2010 Jun 30;2(38):38ra46. doi: 10.1126/scitranslmed.3000976. |
|
2009 |
|
Politis M, Wu K, Piccini P. Positron emission tomography in Parkinson’s disease. Minerva Psychiatr 2009; 50: 50-78. |
|
Wu K, Politis M, Piccini P. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad Med J. 2009 Nov;85(1009):590-6. doi: 10.1136/pgmj.2008.075820. |
|
2008 |
|
Politis M, Pilinis C, Lekkas TD. Ultrafine particles (UFP) and health effects. Dangerous. Like no other PM? Review and Analysis. Global Nest Journal 2008; 10(3): 439-452. https://doi.org/10.30955/gnj.000579 |
|
Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain. 2008 Nov;131(Pt 11):2860-9. doi: 10.1093/brain/awn244. |
|
Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol. 2008 Nov;214(1):112-6. doi: 10.1016/j.expneurol.2008.07.021 |
